Dose reduction and contraindication of the novel oral anticoagulant in patients with heart failure and reduced ejection fraction during a follow-up of 27 month. Data from CORONA Trial
Event:
HEART FAILURE 2016
Topic:
Drug therapy, other
Session:
Drug therapy, other